Introduction to economic modeling for clinical rheumatologists: Application to biologic agents in rheumatoid arthritis

Clinical Rheumatology

Volumn 30, Issue SUPPL. 1, 2011, Pages

  Marra, Carlo A ^a,b,c   Bansback, Nick ^c   Anis, Aslam H ^a,c   Shojania, Kamran ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

Economic evaluation; Modeling; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; PRIORITY JOURNAL; PUBLIC HEALTH INSURANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DECISION MAKING; HUMANS; MODELS, ECONOMIC;

EID: 79955603747     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1635-8     Document Type: Review

References (62)

1. MJ Buxton MF Drummond BA Van Hout RL Prince TA Sheldon, et al. 1997 Modelling in economic evaluation: an unavoidable fact of life Health Econ 6 217 227 9226140 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W 1:STN:280:DyaK2szmvFKqsg%3D%3D (Pubitemid 27296586)
2. MJ Sculpher K Claxton M Drummond C McCabe 2006 Whither trial-based economic evaluation for health care decision-making? Health Econ 15 677 687 16491461 10.1002/hec.1093 (Pubitemid 44057239)
3. P Barton S Bryan S Robinson 2004 Modelling in the economic evaluation of health care: selecting the appropriate approach J Health Serv Res Policy 9 110 118 15099459 10.1258/135581904322987535 (Pubitemid 38568540)
4. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Economic evaluation using decision analytic modelling, chapter 9. In: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford
5. Briggs A, Sculpher M, Claxton K (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
6. MC Tan DA Regier JM Esdaile LD Lynd AH Anis CA Marra 2006 Health economic evaluation: a primer for the practicing rheumatologist Arthritis Rheum 55 648 656 16874788 10.1002/art.22105 (Pubitemid 44289886)
7. G Kobelt P Lindgren A Singh L Klareskog 2005 Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial Ann Rheum Dis 64 1174 1179 15708879 10.1136/ard.2004.032789 1:CAS:528:DC%2BD2MXpslGmsrY%3D (Pubitemid 41113352)
8. G Kobelt L Jonsson A Young K Eberhardt 2003 The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study Rheumatology 42 326 335 12595631 10.1093/rheumatology/keg107 1:STN:280:DC%2BD3s%2FosVCruw%3D%3D (Pubitemid 36305621)
9. A Brennan N Bansback A Reynolds P Conway 2004 Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Rheumatology 43 62 72 12890861 10.1093/rheumatology/keg451 1:STN:280: DC%2BD3sngtVSltQ%3D%3D (Pubitemid 38088370)
10. NJ Bansback A Brennan O Ghatnekar 2005 Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Ann Rheum Dis 64 995 1002 15550533 10.1136/ard.2004.027565 1:STN:280:DC%2BD2MzhtVKgsw%3D%3D (Pubitemid 40909512)
11. AJ Wailoo N Bansback A Brennan K Michaud RM Nixon F Wolfe 2008 Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis Arthritis Rheum 58 939 946 18383356 10.1002/art.23374 (Pubitemid 351563994)
12. A Brennan NJ Bansback RM Nixon J Madan MJ Harrison K Watson, et al. 2007 Modeling the cost effectiveness of TNF alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry Rheumatology 46 1345 1354 17562686 10.1093/rheumatology/ kem115 1:CAS:528:DC%2BD2sXos12iu78%3D (Pubitemid 47244512)
13. Clark W, Jobanputra P, Barton P, Burls A (2004) The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess 8:iii-iv, ix-x, 1-105
14. P Jobanputra P Barton S Bryan A Burls 2002 The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation Health Technol Assess 6 1 110 12387732 1:STN:280:DC%2BD38njtFWqtQ%3D%3D
15. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W et al (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10:iii-iv, xi-xiii, 1-229
16. PM Welsing JL Severens M Hartman PL van Riel RF Laan 2004 Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands Arthritis Rheum 51 964 973 15593319 10.1002/art.20843 (Pubitemid 39648190)
17. HK Choi JD Seeger KM Kuntz 2002 A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis J Rheumatol 29 1156 1165 12064828 (Pubitemid 34601947)
18. HK Choi JD Seeger KM Kuntz 2000 A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis Arthritis Rheum 43 2316 2327 11037892 10.1002/1529-0131(200010)43:10<2316:: AID-ANR20>3.0.CO;2-6 1:STN:280:DC%2BD3cvoslKgtg%3D%3D
19. M Barbieri JB Wong M Drummond 2005 The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK Pharmacoeconomics 23 607 618 15960556 10.2165/00019053-200523060-00007 1:CAS:528: DC%2BD2MXos1alsL4%3D (Pubitemid 40994128)
20. JB Wong G Singh A Kavanaugh 2002 Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis Am J Med 113 400 408 12401535 10.1016/S0002-9343(02)01243-3 (Pubitemid 35223612)
21. CF Chiou J Choi C Reyes 2004 Cost-effectiveness of biological treatments for rheumatoid arthritis Expert Rev Pharmacoecon Outcomes Res 4 307 315 19807313 10.1586/14737167.4.3.307 (Pubitemid 38745087)
22. M Tanno I Nakamura K Ito H Tanaka H Ohta M Kobayashi, et al. 2006 Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis Mod Rheumatol 16 77 84 16633926 10.1007/s10165-006-0461-y
23. Coyle D, Judd M, Blumenauer B, Cranney A, Maetzel A, Tugwell P et al (2006) Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation. Technology report no. 64. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa
24. CA Marra SA Marion DP Guh M Najafzadeh F Wolfe, et al. 2007 Not all "quality-adjusted life years" are equal J Clin Epidemiol 60 616 624 17493521 10.1016/j.jclinepi.2006.09.006 1:STN:280:DC%2BD2szjtVKqsw%3D%3D (Pubitemid 46711077)
25. JR Spalding J Hay 2006 Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis Pharmacoeconomics 24 1221 1232 17129076 10.2165/00019053-200624120-00006 (Pubitemid 44901677)
26. M Vera-Llonch E Massarotti F Wolfe N Shadick R Westhovens, et al. 2008 Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate Rheumatology 47 535 541 18356179 10.1093/rheumatology/ken007 1:CAS:528:DC%2BD1cXmslKhtbo%3D
27. P Lindgren P Geborek G Kobelt 2009 Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden Int J Technol Assess Health Care 25 181 189 19331709 10.1017/S0266462309090230
28. M Vera-Llonch E Massarotti F Wolfe N Shadick R Westhovens O Sofrygin R Maclean T Li G Oster 2008 Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists J Rheumatol 35 1745 1753 18634164 1:CAS:528:DC%2BD1cXhtFyqtbvO
29. A Kielhorn D Porter A Diamantopoulos G Lewis 2008 UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug Curr Med Res Opin 24 2639 2650 18687164 10.1185/03007990802321683 1:CAS:528: DC%2BD1cXhtlKit7vO
30. A Russell A Beresniak L Bessette B Haraoui P Rahman, et al. 2009 Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis Clin Rheumatol 28 403 412 19089488 10.1007/s10067-008-1060- 4
31. N Bansback R Ara J Karnon A Anis 2008 Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health states Pharmacoeconomics 26 395 408 18429656 10.2165/00019053-200826050-00004 (Pubitemid 351572052)
32. CA Marra JC Woolcott JA Kopec K Shojania R Offer, et al. 2005 A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis Soc Sci Med 60 1571 1582 15652688 10.1016/j.socscimed.2004.08.034 (Pubitemid 40126441)
33. NJ Bansback CA Marra A Tsuchiya, et al. 2007 Using the Health Assessment Questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis Arthritis Rheum 57 2963 2977 10.1002/art.22885 (Pubitemid 47237321)
34. LT Jacobsson Y Lindroth L Marsal E Juran U Bergström G Kobelt 2007 Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden Scand J Rheumatol 36 179 183 17657670 10.1080/03009740601089580 1:STN:280:DC%2BD2svjvFShsw%3D%3D (Pubitemid 47174541)
35. RC Kessler JR Maclean M Petukhova CA Sarawate L Short TT Li PE Stang 2008 The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples J Occup Environ Med 50 88 98 18188086 10.1097/JOM.0b013e31815bc1aa
36. TM Farragher M Lunt DK Bunn AJ Silman DP Symmons 2007 Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register Ann Rheum Dis 66 486 492 17090565 10.1136/ard.2006.056390 (Pubitemid 46580469)
37. F Wolfe K Michaud T Pincus 2004 Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire Arthritis Rheum 50 3296 3305 15476213 10.1002/art.20549 (Pubitemid 39372007)
38. F Wolfe 2002 The psychometrics of functional status questionnaires: room for improvement J Rheumatol 29 865 868 12022341 (Pubitemid 34493484)
39. DL Scott B Khoshaba EH Choy GH Kingsley 2007 Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ Ann Rheum Dis 66 1534 1537 17660223 10.1136/ard.2007.073726 1:STN:280: DC%2BD2snkslKrtw%3D%3D (Pubitemid 350032666)
40. TK Kvien 2004 Epidemiology and burden of illness of rheumatoid arthritis Pharmacoeconomics 22 2 Suppl 1 1 12 15157000 (Pubitemid 38269929)
41. X Li MA Gignac AH Anis 2006 The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work Med Care 44 304 310 16565630 10.1097/01.mlr.0000204257.25875.04 (Pubitemid 43755433)
42. F Wolfe K Michaud O Gefeller, et al. 2003 Predicting mortality in patients with rheumatoid arthritis Arthritis Rheum 48 1530 1542 12794820 10.1002/art.11024 (Pubitemid 36682360)
43. E Yelin LF Callahan 1995 The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Work Groups Arthritis Rheum 38 1351 1362 7575685 10.1002/art.1780381002 1:STN:280: DyaK28%2FhslCgsQ%3D%3D
44. KM Pugner DI Scott JW Holmes K Hieke 2000 The costs of rheumatoid arthritis: an international long-term view Semin Arthritis Rheum 29 305 320 10805355 10.1016/S0049-0172(00)80017-7 1:STN:280:DC%2BD3c3mtlWjtw%3D%3D (Pubitemid 30235982)
45. ME Weinblatt JM Kremer AD Bankhurst KJ Bulpitt RM Fleischmann RI Fox, et al. 1999 A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 253 259 9920948 10.1056/NEJM199901283400401 1:CAS:528: DyaK1MXht1Wqsbk%3D (Pubitemid 29063266)
46. R Maini EW St Clair F Breedveld D Furst J Kalden M Weisman, et al. 1999 Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1932 1939 10622295 10.1016/S0140-6736(99)05246-0 1:CAS:528:DC%2BD3cXit1Oquw%3D%3D
47. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, et al. 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 1594 1602 11096166 10.1056/ NEJM200011303432202 1:CAS:528:DC%2BD3cXovVeltLk%3D (Pubitemid 32162982)
48. MC Genovese JM Bathon RW Martin RM Fleischmann JR Tesser MH Schiff, et al. 2002 Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes Arthritis Rheum 46 1443 1450 12115173 10.1002/art.10308 1:CAS:528:DC%2BD38Xltlantbk%3D (Pubitemid 34620189)
49. LB van de Putte R Rau FC Breedveld JR Kalden MG Malaise PL van Riel, et al. 2003 Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study Ann Rheum Dis 62 1168 1177 14644854 10.1136/ard.2003.009563 (Pubitemid 37500622)
50. ME Weinblatt EC Keystone DE Furst LW Moreland MH Weisman CA Birbara, et al. 2003 Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum 48 35 45 12528101 10.1002/art.10697 1:CAS:528:DC%2BD3sXhtFGnsb0%3D (Pubitemid 36091645)
51. RN Maini FC Breedveld JR Kalden JS Smolen D Furst MH Weisman Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, et al. 2004 Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate Arthritis Rheum 50 1051 1065 15077287 10.1002/art.20159 1:CAS:528:DC%2BD2cXjslGqsrk%3D (Pubitemid 38480815)
52. L Klareskog D van der Heijde JP de Jager A Gough J Kalden M Malaise TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators, et al. 2004 Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 675 681 15001324 10.1016/S0140-6736(04)15640-7 1:CAS:528:DC%2BD2cXhs12jur4%3D (Pubitemid 38296553)
53. E Keystone A Kavanaugh J Sharp H Tennenbaum Y Hua L Teoh, et al. 2004 Radiographic, clinical, and functional outcomes with adalimumab (a human anti-TNF alpha monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methotrexate therapy: a randomized, controlled, 52 week-trial Arthritis Rheum 50 1400 1411 15146409 10.1002/art.20217 1:CAS:528:DC%2BD2cXkvFykur4%3D (Pubitemid 38608061)
54. Lopez-Olivo M, Amezaga M, McGahan L, Suarez-Almazor M (2008) Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 2008(4):CD007356
55. JM Polinksi PE Mohr L Johnson 2009 Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis Arthritis Rheum 61 745 754 10.1002/art.24560
56. DH Solomon A Kavanaugh 2008 The economics of rheumatoid arthritis management Int J Adv Rheumatol 6 2 5
57. J Sorensen LS Andersen 2005 The case of tumour necrosis factor alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis Pharmacoeconomics 23 289 298 15836009 10.2165/00019053-200523030-00008 1:CAS:528:DC%2BD2MXltFSjsbs%3D (Pubitemid 40663634)
58. National Institute of Clinical Excellence (2007) Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 130. Available at: http://www.nice.org.uk/nicemedia/pdf/ TA130guidance.pdf. Accessed August 2010
59. F Wolfe K Michaud T Pincus 2004 Do rheumatology cost-effectiveness analyses make sense? Rheumatology 43 4 6 14523227 10.1093/rheumatology/keh034 1:STN:280:DC%2BD3sngtVSktw%3D%3D (Pubitemid 38088359)
60. A Maetzel 2005 Cost-effectiveness analysis: out of touch with clinical reality? Arthritis Rheum (Arthritis Care Res) 53 3 4 10.1002/art.20906 (Pubitemid 40216344)
61. P Emery 2004 Review of health economics modeling in rheumatoid arthritis Pharmacoeconomics 22 Suppl 1 55 69 15157004 (Pubitemid 38269932)
62. NJ Bansback DA Regier R Ara A Brennan K Shojania, et al. 2005 An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists Drugs 65 473 496 15733011 10.2165/00003495-200565040-00004 (Pubitemid 40469553)